New hormone targets GLP‑1 brain area
- Researchers reported that the hormone FGF21 targets the same brain region as GLP‑1 drugs but may act differently. - A University of Oklahoma study in Cell Reports suggests FGF21 might boost metabolic rate rather than mainly suppress appetite. - Scientists presented this as an alternative metabolic mechanism that could broaden obesity-therapy approaches (foxnews.com).
Obesity drugs often work by telling the brain to eat less. A new mouse study says another hormone hits the same brain hub but seems to make the body burn more energy instead. (cell.com) The hormone is fibroblast growth factor 21, or FGF21, a natural signal made in the body. University of Oklahoma researchers reported on April 1, 2026 that FGF21 acts in the hindbrain, not the hypothalamus they expected, and published the work in *Cell Reports*. (ou.edu) In the study, FGF21 signaled to two hindbrain structures — the nucleus of the solitary tract and the area postrema — which then relayed the signal to the parabrachial nucleus. The paper describes that circuit as necessary for the weight-reducing metabolic effects the team saw in mice given pharmacologic FGF21. (ou.edu; cell.com) Glucagon-like peptide-1 drugs such as Wegovy and Ozempic are widely understood to lower body weight mainly by reducing food intake through brain pathways. Matthew Potthoff, a biochemistry and physiology professor at the OU College of Medicine, said FGF21 appears to use the same general hindbrain neighborhood differently by increasing metabolic rate. (ou.edu) That distinction matters because obesity treatment has centered on appetite suppression, while this study points to energy expenditure — how many calories the body burns — as a separate lever. The paper frames the finding as a brain-circuit explanation for how FGF21 can reverse obesity in mice after earlier work had shown the hormone signals through the brain. (cell.com; cell.com) The work is still preclinical. The OU release and the *Cell Reports* paper both describe mouse experiments, not a human weight-loss trial, so the results do not show that FGF21 will reduce obesity in people without lowering calorie intake. (ou.edu; cell.com) FGF21 is not a brand-new target. Drug versions of the hormone are already in development for metabolic dysfunction-associated steatohepatitis, or MASH, a serious fatty liver disease, and one FGF21 analogue, efruxifermin, is in Phase 3 testing, according to ClinicalTrials.gov and Akero Therapeutics. (clinicaltrials.gov; akerotx.com) Another FGF21 analogue, pegozafermin, showed fibrosis improvement in a phase 2b MASH trial published in *The New England Journal of Medicine*, and 89bio says its Phase 3 MASH program is underway. Those liver-disease programs suggest companies already see FGF21 biology as druggable, even before any obesity medicine based on this mechanism reaches late-stage testing. (nejm.org; 89bio.com) Potthoff said identifying the exact circuit could help researchers design more targeted therapies and possibly avoid some side effects seen with FGF21 analogues, including gastrointestinal problems and, in some cases, bone loss. For now, the finding adds a new brain map for a hormone researchers hope could widen the menu of obesity and MASH treatments. (ou.edu)
